Full Press Release Details
USANA Health Sciences Reports Third Quarter 2023 Results
SALT LAKE CITY--(BUSINESS WIRE)--October 24, 2023--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 30, 2023.
Key Financial & Operating Results
Third quarter net sales were $213 million versus $233 million during Q3 2022.
Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022.
Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).
Q3 2023 Financial Performance
| Consolidated Results | ||
| Net Sales | $213 million | -9% vs. Q3 2022 -7% constant currency vs. Q3 2022 -$5 million YOY FX impact, or -2% -10% sequentially -9% constant currency sequentially |
| Diluted EPS | $0.59 | -24% vs. Q3 2022 -34% sequentially Diluted shares of 19.4 million, or +1% year-over-year |
| Active Customers | 464,000 | -2% vs. Q3 2022 -5% sequentially |
"Operating results for the third quarter did not meet our expectations, largely because of challenging economic conditions across many of our regions and a lower cadence of promotional activity during the quarter," said Jim Brown, President
and Chief Executive Officer. "These factors made it difficult to generate both Active Customer growth and top line momentum in our business. Notwithstanding these near-term challenges, the strength of our balance sheet and business model
allowed us to continue investing in key strategic initiatives during the quarter, and we plan to continue to invest in and execute these strategies going forward. We also believe that the expanding global nutrition category, and consumers'
increased focus on health and wellness, provide a compelling opportunity for us to leverage our best-in-class health products and business opportunity. Consequently, we remain confident and optimistic that our strategies will generate long-term
Active Customer and sales growth for USANA."
Mr. Brown continued, "We made progress on several initiatives during the quarter, including the re-engagement of our Associate leaders around the world. During the quarter, we hosted a successful Americas and Europe convention in Salt Lake
City. We believe that these in-person events are key to generating momentum and excitement among our Associates, and we have more events planned over the next 12 months."
"During the quarter, we also finalized plans to commence operations in India and anticipate opening this important market prior to year-end. We continue to believe that India provides a meaningful and diverse growth opportunity for USANA, and
we are excited to introduce our best-in-class nutritional products in this promising market."
Q3 2023 Regional Results:
| Asia Pacific Region | ||
| Net Sales | $170 million | -7% vs. Q3 2022 -4% constant currency vs. Q3 2022 -12% sequentially -10% constant currency sequentially 80% of consolidated net sales |
| Active Customers | 362,000 | Flat vs. Q3 2022 -6% sequentially |
| Asia Pacific Sub-Regions | ||
| Greater China | ||
| Net Sales | $107 million | -3% vs. Q3 2022 +2% constant currency vs. Q3 2022 -17% sequentially -15% constant currency sequentially |
| Active Customers | 230,000 | +8% vs. Q3 2022 -8% sequentially |
| North Asia | ||
| Net Sales | $24 million | -6% vs. Q3 2022 -7% constant currency vs. Q3 2022 -5% sequentially -5% constant currency sequentially |
| Active Customers | 49,000 | -9% vs. Q3 2022 -4% sequentially |
| Southeast Asia Pacific | ||
| Net Sales | $39 million | -17% vs. Q3 2022 -16% constant currency vs. Q3 2022 Flat sequentially +1% constant currency sequentially |
| Active Customers | 83,000 | -13% vs. Q3 2022 +1% sequentially |
| Americas and Europe Region | ||
| Net Sales | $43 million | -14% vs. Q3 2022 -16% constant currency vs. Q3 2022 -3% sequentially -3% constant currency sequentially 20% of consolidated net sales |
| Active Customers | 102,000 | -9% vs. Q3 2022 -1% sequentially |
Balance Sheet and Share Repurchase Activity
The Company generated $22 million in operating cash flow during the third quarter and ended the quarter with $307 million in cash and cash equivalents while remaining debt-free. The Company repurchased 180 thousand shares for a total of $12
million during the quarter. As of September 30, 2023, the Company had approximately $71 million remaining under the current share repurchase authorization.
Fiscal Year 2023 Outlook
The Company is revising its net sales and earnings per share outlook for fiscal year 2023, as follows:
| Fiscal Year 2023 Outlook | ||
| Revised Range | Previous Range | |
| Consolidated Net Sales | $900 - $920 million | $900 - $950 million |
| Diluted EPS | $2.80 - $3.05 | $2.65 - $3.30 |
"Inflationary pressures, lower promotional activity, and the strengthening of the US dollar collectively resulted in lower than anticipated top line performance," said Doug Hekking, Chief Financial Officer. "Additionally, we updated our
annual effective tax rate estimate during the quarter, which negatively impacted third quarter EPS by approximately $0.10 per share due to the relative distribution of taxable income by market."
Mr. Hekking continued, "We are narrowing our fiscal 2023 guidance to reflect our third quarter operating results, expected fourth quarter results, and continued pressure from unfavorable foreign currency exchange rates. We remain committed to
managing costs in line with expected sales performance while we continue to invest in strategic initiatives that we believe will drive sustainable long-term growth for USANA."
Management Commentary Document and Conference Call
For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will
hold a conference call and webcast to discuss today's announcement with investors on Wednesday, October 25, 2023 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call
will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are
non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional
perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period
and then comparing this amount to the prior-year period's Financial Results.
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong
Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be
found at www.usana.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these
forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the COVID-19 pandemic ("COVID-19") to our business, operations and financial results; the potential for a resurgence of COVID-19
spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in
connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations
between the United States and China; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict and
the conflict in Israel; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions
generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with
governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S.
and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange
Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to
actual results or changes in the Company's expectations, except as required by law.
| USANA Health Sciences, Inc. | ||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Quarter Ended | Nine Months Ended | |||||||||||||||
| 30-Sep-23 | 1-Oct-22 | 30-Sep-23 | 1-Oct-22 | |||||||||||||
| Net sales | $ | 213,365 | $ | 233,300 | $ | 699,927 | $ | 770,641 | ||||||||
| Cost of sales | 42,529 | 46,560 | 134,374 | 147,460 | ||||||||||||
| Gross profit | 170,836 | 186,740 | 565,553 | 623,181 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Associate incentives | 89,926 | 98,090 | 298,376 | 336,914 | ||||||||||||
| Selling, general and administrative | 63,303 | 66,020 | 198,325 | 201,204 | ||||||||||||
| Earnings from operations | 17,607 | 22,630 | 68,852 | 85,063 | ||||||||||||
| Other income (expense), net | 2,924 | 594 | 6,990 | 756 | ||||||||||||
| Earnings before income taxes | 20,531 | 23,224 | 75,842 | 85,819 | ||||||||||||
| Income taxes | 9,184 | 8,295 | 28,820 | 29,264 | ||||||||||||
| NET EARNINGS | $ | 11,347 | $ | 14,929 | $ | 47,022 | $ | 56,555 | ||||||||
| Earnings per share - diluted | $ | 0.59 | $ | 0.78 | $ | 2.43 | $ | 2.93 | ||||||||
| Weighted average shares outstanding - diluted | 19,372 | 19,252 | 19,376 | 19,325 |
| USANA Health Sciences, Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (In thousands) | ||||||||
| (Unaudited) | ||||||||
| As of | As of | |||||||
| 30-Sep-23 | 31-Dec-22 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 307,081 | $ | 288,420 | ||||
| Inventories | 60,081 | 67,089 | ||||||
| Prepaid expenses and other current assets | 23,298 | 28,873 | ||||||
| Total current assets | 390,460 | 384,382 | ||||||
| Property and equipment, net | 95,159 | 97,773 | ||||||
| Goodwill | 16,801 | 17,368 | ||||||
| Intangible assets, net | 29,462 | 32,432 | ||||||
| Deferred tax assets | 15,135 | 9,799 | ||||||
| Other assets* | 54,131 | 54,795 | ||||||
| Total assets | $ | 601,148 | $ | 596,549 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 9,321 | $ | 11,049 | ||||
| Other current liabilities | 103,238 | 132,784 | ||||||
| Total current liabilities | 112,559 | 143,833 | ||||||
| Deferred tax liabilities | 4,747 | 4,071 | ||||||
| Other long-term liabilities | 13,448 | 14,173 | ||||||
| Stockholders' equity | 470,394 | 434,472 | ||||||
| Total liabilities and stockholders' equity | $ | 601,148 | $ | 596,549 |
| USANA Health Sciences, Inc. | ||||||||||||||||||||||||||||
| Sales by Region | ||||||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||
| Quarter Ended | ||||||||||||||||||||||||||||
| September 30, 2023 | October 1, 2022 | Change from prior year | Currency impact on sales | % change excluding currency impact | ||||||||||||||||||||||||
| Asia Pacific | ||||||||||||||||||||||||||||
| Greater China | $ | 106,609 | 50.0 | % | $ | 109,682 | 47.0 | % | $ | (3,073 | ) | (2.8 | %) | $ | (5,377 | ) | 2.1 | % | ||||||||||
| Southeast Asia Pacific | 39,151 | 18.3 | % | 47,308 | 20.3 | % | (8,157 | ) | (17.2 | %) | (532 | ) | (16.1 | %) | ||||||||||||||
| North Asia | 24,244 | 11.4 | % | 25,667 | 11.0 | % | (1,423 | ) | (5.5 | %) | 487 | (7.4 | %) | |||||||||||||||
| Asia Pacific Total | 170,004 | 79.7 | % | 182,657 | 78.3 | % | (12,653 | ) | (6.9 | %) | (5,422 | ) | (4.0 | %) | ||||||||||||||
| Americas and Europe | 43,361 | 20.3 | % | 50,643 | 21.7 | % | (7,282 | ) | (14.4 | %) | 745 | (15.9 | %) | |||||||||||||||
| $ | 213,365 | 100.0 | % | $ | 233,300 | 100.0 | % | $ | (19,935 | ) | (8.5 | %) | $ | (4,677 | ) | (6.5 | %) |
| Active Associates by Region (1) | ||||||||||||
| (Unaudited) | ||||||||||||
| As of | ||||||||||||
| September 30, 2023 | October 1, 2022 | |||||||||||
| Asia Pacific | ||||||||||||
| Greater China | 69,000 | 34.0 | % | 73,000 | 32.5 | % | ||||||
| Southeast Asia Pacific | 55,000 | 27.1 | % | 68,000 | 30.2 | % | ||||||
| North Asia | 33,000 | 16.2 | % | 34,000 | 15.1 | % | ||||||
| Asia Pacific Total | 157,000 | 77.3 | % | 175,000 | 77.8 | % | ||||||
| Americas and Europe | 46,000 | 22.7 | % | 50,000 | 22.2 | % | ||||||
| 203,000 | 100.0 | % | 225,000 | 100.0 | % |
| Active Preferred Customers by Region (2) | ||||||||||||
| (Unaudited) | ||||||||||||
| As of | ||||||||||||
| September 30, 2023 | October 1, 2022 | |||||||||||
| Asia Pacific | ||||||||||||
| Greater China | 161,000 | 61.7 | % | 140,000 | 56.2 | % | ||||||
| Southeast Asia Pacific | 28,000 | 10.7 | % | 27,000 | 10.9 | % | ||||||
| North Asia | 16,000 | 6.1 | % | 20,000 | 8.0 | % | ||||||
| Asia Pacific Total | 205,000 | 78.5 | % | 187,000 | 75.1 | % | ||||||
| Americas and Europe | 56,000 | 21.5 | % | 62,000 | 24.9 | % | ||||||
| 261,000 | 100.0 | % | 249,000 | 100.0 | % |
| (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale. |
| (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market. |